Position Paper ‘Clinical Trials’
This joint statement of scientifically oriented study groups in gynecologic oncology emphasizes the outstanding importance of trial participation for the quality assurance of individual clinics and solicits sustainable understanding of the networks within a clinic participation as an investigational center in a trial.
Opinion: Ovarian cancer – is intraperitoneal therapy really the new standard?
Andreas du Bois, Barbara Schmalfeldt, Werner Meier, Jalid Sehouli, Jacobus Pfisterer for the AGO Ovarian Commission, the AGO Ovarian Cancer Study Group (AGO-OVAR) and the NOGGO
Whith the publication of the GOG 172 trial in the New England Journal of Medicine in January of this year, intraperitoneal chemotherapy in patients with ovarian cancer has become the focus of both professional and media interest. In part, ip therapy has already been proclaimed as the new standard therapy based on thes trial…
Neoadjuvant chemotherapy cannot be considered standard therapy for ovarian cancer
Jalid Sehouli, Uwe Wagner, Martin Pölcher, Andreas du Bois for the Ovary Commission of the Working Group for Gynecological Oncology (AGO) and the two cooperative study groups in Germany, AGO Study Group and NOGGO
With the presentation and publication of the EORTC-GCG/NCIC-CTG trial on neoadjuvant therapy of ovarian cancer, the discussion on the optimal sequence of the individual forms of therapy in the multimodality therapy concept has been renewed (1,2a,b). The Ovarian Commission of AGO issues the following statement in addition to the current guideline:
‘Even with the data available in 2010, neoadjuvant chemotherapy cannot be recommended as standard therapy for ovarian cancer and should be offered outside of trials only to patients who have contraindications to pramary surgery.’ …
Bevacizumab in first-line therapy of ovarian cancer
Statement of the Ovary Commission of the Working Group of Gynecologic Oncology (Arbeitsgemeinschaft Gynäkologische Onkologie, AGO)
For the Commission: S. Mahner, A. du Bois, J. Sehouli, J. Pfisterer, U. Wagner
In June 2010, the American Gynecologic Oncology Group (GOG) presented the phase III GOG-218 trial on the use of bevacizumab in first-line therapy of ovarian cancer at the American Society of Clinical Oncology (ASCO) Congress. (1) The results and critical conclusions are discussed here.
Statement by the OVARY Commission of the AGO Study Group on the Use of HIPEC (Hyperthermic Intraperitoneal Chemotherapy) to Treat Primary and Recurrent Ovarian Cancer
P. Harter, S. Mahner, F. Hilpert, I. Runnebaum, O. Ortmann, A. Mustea, J. Sehouli, A. du Bois, U. Wagner, for the Kommission Ovar of the Arbeitsgemeinschaft Gynäkologische Onkologie
HIPEC is offered to patients with ovarian, fallopian tube or primary peritoneal cancer at some hospitals. Altogether, there is still no evidence that HIPEC leads to an improvement of prognosis in any gynecologic tumor, neither in primary therapy nor in treatment of relapse…